Impact of NSAID type, initiation timing, duration and dose on clinical outcomes of immunotherapy in NSCLC: a multicenter two-cohort study - PubMed
10 hours ago
- #NSCLC
- #Immunotherapy
- #NSAIDs
- NSAID use was independently associated with improved progression-free survival (PFS) and overall survival (OS) in advanced NSCLC patients undergoing immunotherapy.
- Both NSAID use before and after initiation of immune checkpoint inhibitors (ICI) showed benefits, with after-ICI initiation particularly improving OS for non-selective NSAIDs.
- Low-dose aspirin users had better PFS than non-users, especially when used for at least 30 days, and aspirin was linked to reduced prostaglandin E2 (PGE2) levels.
- NSAID use was associated with decreased neutrophils in circulation and tumor, suggesting PGE2 and neutrophils as potential biomarkers for NSAID-immunotherapy integration.
- Adverse event rates were comparable between NSAID users and non-users, indicating no increased toxicity from NSAID combination with immunotherapy.